Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California. Show more

10955 Alexandria Way, San Diego, CA, 92121, United States

Biotechnology

Healthcare

Market Cap

26.66M

52 Wk Range

$0.96 - $1.78

Previous Close

$1.15

Open

$1.17

Volume

124,745

Day Range

$1.16 - $1.22

Enterprise Value

-31.88M

Cash

107.6M

Avg Qtr Burn

-10.11M

Insider Ownership

11.38%

Institutional Own.

51.21%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BBI-940 Details Indication unknown (ecDNA segregation and inheritance)	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BBI-355 + BBI-825 Details Locally advanced or metastatic solid tumors with oncogene amplifications	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.